What is Chardan Capital’s Estimate for FBRX FY2025 Earnings?

Forte Biosciences, Inc. (NASDAQ:FBRX) – Investment analysts at Chardan Capital lowered their FY2025 earnings estimates for Forte Biosciences in a research note issued on Wednesday, April 2nd. Chardan Capital analyst D. Gataulin now anticipates that the company will post earnings of ($4.25) per share for the year, down from their previous estimate of ($4.03). Chardan Capital has a “Buy” rating and a $61.00 price target on the stock. The consensus estimate for Forte Biosciences’ current full-year earnings is ($12.12) per share. Chardan Capital also issued estimates for Forte Biosciences’ FY2026 earnings at ($2.04) EPS.

Separately, TD Cowen assumed coverage on Forte Biosciences in a research report on Tuesday, January 21st. They set a “buy” rating for the company.

Forte Biosciences Price Performance

FBRX opened at $5.34 on Monday. The firm has a market capitalization of $35.15 million, a P/E ratio of -0.33 and a beta of 2.52. Forte Biosciences has a one year low of $4.11 and a one year high of $28.68. The company has a fifty day moving average price of $9.34 and a 200-day moving average price of $11.66.

Hedge Funds Weigh In On Forte Biosciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Woodline Partners LP purchased a new stake in shares of Forte Biosciences during the 4th quarter valued at $4,639,000. Tybourne Capital Management HK Ltd. increased its stake in Forte Biosciences by 327.6% in the fourth quarter. Tybourne Capital Management HK Ltd. now owns 619,981 shares of the company’s stock valued at $14,080,000 after acquiring an additional 475,000 shares during the last quarter. Orbimed Advisors LLC purchased a new stake in Forte Biosciences during the fourth quarter valued at about $13,626,000. Fred Alger Management LLC lifted its stake in Forte Biosciences by 1,271.2% during the fourth quarter. Fred Alger Management LLC now owns 1,133,944 shares of the company’s stock worth $25,752,000 after purchasing an additional 1,051,246 shares during the last quarter. Finally, BVF Inc. IL boosted its holdings in shares of Forte Biosciences by 398.2% in the 4th quarter. BVF Inc. IL now owns 594,282 shares of the company’s stock worth $13,496,000 after purchasing an additional 475,000 shares in the last quarter. Hedge funds and other institutional investors own 77.63% of the company’s stock.

Forte Biosciences Company Profile

Forte Biosciences, Inc operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc is headquartered in Dallas, Texas.